Products Categories
| CAS No.: | 59333-67-4 |
|---|---|
| Name: | Fluoxetine hydrochloride |
| Article Data: | 33 |
| Molecular Structure: | |
|
|
|
| Formula: | C17H18F3NO.HCl |
| Molecular Weight: | 309.331 |
| Synonyms: | Methyl[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]amine hydrochloride;N-Methyl-gama-[4-(trifluoromethyl);Motivone;CCRIS 7093;Cramin;Depreks;Digassim;Felicium;Equilibrane;Fluoxetine HCl; |
| EINECS: | 260-101-2 |
| Density: | 1.254g/cm3 |
| Melting Point: | 158-159 °C |
| Boiling Point: | 395.1 °C at 760 mmHg |
| Flash Point: | 192.8 °C |
| Solubility: | water: 4 mg/mL |
| Appearance: | white to off-white powder |
| Hazard Symbols: |
 Xn
|
| Risk Codes: | 22-38-41 |
| Safety: | 26-36/37/39 |
| PSA: | 21.26000 |
| LogP: | 5.62790 |
- 81281-59-67-Benzylideneaminotheophylline
- 82993-81-5D-threo-Ritalinic acid hydrochloride
- 73441-42-6METHYL-5-CHLORO-2,2-DIMETHYLVALERATE
- 68439-39-4Poly(oxy-1,2-ethanediyl), alpha-(2-ethylhexyl)-omega-hydroxy-,
- 852475-26-4MC1568
- 958254-66-51H-Imidazo[4,5-b]pyridine-2-carboxaldehyde, 1-methyl-, hydrochloride
- 99170-93-1N-Methyl-2-oxazolamine
- 717878-06-31-(4-fluorophenyl)-4-nitro-1H-imidazole
- 914458-26-7[5-(2-fluorophenyl)-1-pentyl-1H-pyrrol-3-yl]-1-naphthalenyl-Methanone
- 894852-01-87-BROMO-2,2-DIMETHYL-2H-PYRIDO[3,2-B][1,4]OXAZIN-3(4H)-ONE
- 659-40-5Hexamidine diisethionate
- 5343-92-01,2-Pentanediol
- 6119-70-6Quinine sulfate dihydrate
- 14375-45-22,4-Pentadienoic acid,5-(1-hydroxy-2,6,6-trimethyl-4-oxo-2-cyclohexen-1-yl)-3-methyl-, (2Z,4E)-
- 125-04-2Pregn-4-ene-3,20-dione,21-(3-carboxy-1-oxopropoxy)-11,17-dihydroxy-, sodium salt (1:1), (11b)-
- 106-42-31,4-Dimethylbenzene
- 1398-61-4Chitin
- 8002-09-3Pine oil
- 104987-11-3Tacrolimus
- 141-53-7Sodium formate
- 8001-54-5Quaternary ammonium compounds, alkylbenzyldimethyl, chlorides
- 9003-39-8Povidone
- 10161-34-9Trenbolone acetate
- 402957-28-2Telaprevir
- 68-19-9Cyanocobalamin
What can I do for you?
Get Best Price
Chemistry
Molecular Formula: C17H19ClF3NO
Molecular Weight: 345.7871
EINECS: 260-101-2
Melting point: 158-159 °C
Water solubility: 4 mg/mL
Flash Point: 192.8 °C
Enthalpy of Vaporization: 64.52 kJ/mol
Boiling Point: 395.1 °C at 760 mmHg
Vapour Pressure: 1.88E-06 mmHg at 25 °C
Appearance: White to off-white powder
Structure of Fluoxetine hydrochloride (CAS NO.59333-67-4):
IUPAC Name: N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-aminehydrochloride
Product Category of Fluoxetine hydrochloride (CAS NO.59333-67-4): Active Pharmaceutical Ingredients;Fluorobenzene;APIs;Intermediates & Fine Chemicals;Serotonin receptor
History
According to David Wong, the work which eventually led to the discovery of fluoxetine began at Eli Lilly in 1970 as a collaboration between Bryan Molloy and Robert Rathbun. Testing the physiological effects of these compounds in mice resulted in nisoxetine, a selective norepinephrine reuptake inhibitor currently widely used in biochemical experiments. This test which carried out by Jong-Sir Horng in May 1972, showed the compound later named fluoxetine to be the most strong and selective inhibitor of serotonin reuptake of the series. Two years later they had to issue a correction, admitting that the first SSRI was zimelidine developed by Arvid Carlsson and colleagues. In 1986, Fluoxetine made its appearance on the Belgian market and was approved for use by the FDA in the United States in December 1987. Fluoxetine was the fourth SSRI to make it to market, after zimelidine, indalpine and fluvoxamine.
Uses
Fluoxetine hydrochloride (CAS NO.59333-67-4) can be used as an antidepressant.
Toxicity Data With Reference
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| cat | LD | oral | > 50mg/kg (50mg/kg) | Journal of Clinical Psychiatry. Vol. 46(3, Pg. Sec, | |
| child | TDLo | oral | 26mg/kg (26mg/kg) | CARDIAC: EKG CHANGES NOT DIAGNOSTIC OF ABOVE BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD GASTROINTESTINAL: NAUSEA OR VOMITING | Journal of the American Academy of Child and Adolescent Psychiatry. Vol. 28, Pg. 587, 1989. |
| dog | LD | oral | > 100mg/kg (100mg/kg) | Journal of Clinical Psychiatry. Vol. 46(3, Pg. Sec, | |
| guinea pig | LD | oral | > 250mg/kg (250mg/kg) | Journal of Clinical Psychiatry. Vol. 46(3, Pg. Sec, | |
| human | TDLo | oral | 7770ug/kg (7.77mg/kg) | BEHAVIORAL: TREMOR CARDIAC: ARRHYTHMIAS (INCLUDING CHANGES IN CONDUCTION) GASTROINTESTINAL: NAUSEA OR VOMITING | American Journal of Emergency Medicine. Vol. 10, Pg. 115, 1992. |
| man | TDLo | oral | 3733ug/kg/24H (3.733mg/kg) | BEHAVIORAL: SLEEP BEHAVIORAL: EUPHORIA BEHAVIORAL: AGGRESSION | American Journal of Psychiatry. Vol. 143, Pg. 686, 1985. |
| man | TDLo | oral | 12mg/kg/8W-I (12mg/kg) | BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS" | American Journal of Psychiatry. Vol. 150, Pg. 1750, 1993. |
| man | TDLo | oral | 208mg/kg/2Y-I (208mg/kg) | BEHAVIORAL: ANOREXIA (HUMAN BEHAVIORAL: MUSCLE WEAKNESS LIVER: "JAUNDICE, OTHER OR UNCLASSIFIED" | Mayo Clinic Proceedings. Vol. 74, Pg. 692, 1999. |
| monkey | LD | oral | > 50mg/kg (50mg/kg) | Journal of Clinical Psychiatry. Vol. 46(3, Pg. Sec, | |
| mouse | LD50 | intraperitoneal | 100mg/kg (100mg/kg) | Toxicology and Applied Pharmacology. Vol. 32, Pg. 129, 1975. | |
| mouse | LD50 | oral | 248mg/kg (248mg/kg) | Journal of Clinical Psychiatry. Vol. 46(3, Pg. Sec, | |
| rat | LD50 | oral | 452mg/kg (452mg/kg) | Journal of Clinical Psychiatry. Vol. 46(3, Pg. Sec, | |
| women | TDLo | oral | 400ug/kg (0.4mg/kg) | BEHAVIORAL: EXCITEMENT | Journal of Clinical Psychiatry. Vol. 50, Pg. 339, 1989. |
| women | TDLo | oral | 800ug/kg/2D-I (0.8mg/kg) | CARDIAC: ARRHYTHMIAS (INCLUDING CHANGES IN CONDUCTION) CARDIAC: PULSE RATE | Journal of Clinical Psychiatry. Vol. 52, Pg. 174, 1991. |
| women | TDLo | oral | 2800ug/kg/1W- (2.8mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) | Journal of Clinical Psychiatry. Vol. 55, Pg. 118, 1994. |
| women | TDLo | oral | 5600ug/kg/2W- (5.6mg/kg) | SKIN AND APPENDAGES (SKIN): HAIR: OTHER | British Journal of Psychiatry. Vol. 159, Pg. 737, 1991. |
| women | TDLo | oral | 5600ug/kg/2W- (5.6mg/kg) | BEHAVIORAL: EXCITEMENT BEHAVIORAL: HEADACHE MUSCULOSKELETAL: CHANGES IN TEETH AND SUPPORTING STRUCTURES | Journal of Clinical Psychiatry. Vol. 54, Pg. 432, 1993. |
| women | TDLo | oral | 8mg/kg/4W-I (8mg/kg) | BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY) BEHAVIORAL: HEADACHE | Journal of Clinical Psychiatry. Vol. 54, Pg. 235, 1993. |
| women | TDLo | oral | 8400ug/kg/3W- (8.4mg/kg) | CARDIAC: CHANGE IN RATE VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION | Annals of Emergency Medicine. Vol. 20, Pg. 194, 1991. |
| women | TDLo | oral | 13600ug/kg (13.6mg/kg) | SKIN AND APPENDAGES (SKIN): "DERMATITIS, ALLERGIC: AFTER SYSTEMIC EXPOSURE" SKIN AND APPENDAGES (SKIN): "DERMATITIS, IRRITATIVE: AFTER SYSTEMIC EXPOSURE" | Journal of Toxicology, Clinical Toxicology. Vol. 27, Pg. 389, 1989. |
| women | TDLo | oral | 17mg/kg/2W-I (17mg/kg) | BEHAVIORAL: ANOREXIA (HUMAN | Journal of Clinical Psychiatry. Vol. 55, Pg. 118, 1994. |
| women | TDLo | oral | 28mg/kg/7W-I (28mg/kg) | LUNGS, THORAX, OR RESPIRATION: DYSPNEA | Medical Journal of Australia. Vol. 156, Pg. 364, 1992. |
Safety Profile
Hazard Codes: Xn 
Risk Statements: 22-38-41
22:Harmful if swallowed
38:Irritating to the skin
41:Risk of serious damage to eyes
Safety Statements: 26-36/37/39
26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice
36/37/39:Wear suitable protective clothing, gloves and eye/face protection
Specification
Fluoxetine hydrochloride , its cas register number is 59333-67-4. It also can be called N-Methyl-gama-[4-(trifluoromethyl) ; and Methyl[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]amine hydrochloride .